By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Canbas Co., Ltd. 

2-2-1 Otemachi, Numazu City

Shizuoka    410-0801  Japan
Phone: 81-55-954-3666 Fax: 81-55-954-3668


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Discovery





Company News
Canbas Co., Ltd.: CBP501 Met Primary Endpoint of Phase II Study in Malignant Pleural Mesothelioma 6/4/2012 10:01:18 AM
Canbas Co., Ltd.' CBP501 Receives FDA Orphan Drug Designation for Malignant Mesothelioma 1/5/2012 9:59:04 AM
Canbas Co., Ltd. Announces Last Patient Enrolled in Phase II Trial of CBP501 as First-Line Treatment of Malignant Pleural Mesothelioma 11/1/2011 9:22:42 AM
Canbas Co., Ltd. Announces Last Patient Enrolled in Phase II Trial of CBP501 as First-Line Treatment of Non-Small Cell Lung Cancer 10/27/2011 10:27:51 AM
Canbas Co., Ltd.' Phase II Anti-Cancer Drug CBP501 Mechanisms Include Calmodulin Binding; CBS9106 Inhibits CRM1 4/5/2011 9:11:04 AM
Canbas Co., Ltd. to Present New Data on Phase II Clinical Candidate CBP501 Mechanism of Action and Novel CRM1 Inhibitor CBS9106 at American Association for Cancer Research Annual Meeting 3/17/2011 9:34:48 AM
Takeda Pharmaceutical Co. Ltd. (TKDG.DE), Millennium: The Takeda Oncology Company And Canbas Co., Ltd.: CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer 7/7/2009 9:39:20 AM
Privately Held Drug Discovery Company, Canbas Co., Ltd. Raises $20 Million In 4th Round Financing 1/6/2006 11:00:45 AM
//-->